Table 4.

Selected clinical trials with bendamustine in relapsed MM patients

Alone/ Combination	n	Prior Lines	ORR (≥PR)		PFS (months)	Reference
Single agent	31	-*	31%	7% CR, 24% PR	26	Knop. Haematologica 2005[160]
+ Bort	40	6 (1->7)	27%	2% CR, 5% VGPR, 21%PR	8.4	Berenson. BJH 2013[161]
+ Bort-Dex	40	4 (2–10)	72%	25% VGPR, 47%PR	-	Hrusovsky. ASH 2007[126]
+ Bort-Dex	45	2 (1->4)	51%	15% CR, 6% VGPR, 30% PR	9.4	Ludwig. ASH 2011 [125]
+ Bort-Pred	78	2 (1–9)	69%	30% VGPR, 40% PR	-	Pönisch. J Cancer Res Clin Oncol 2013[162]
+ Thal-Pred	28	2 (1–6)	86%	14% CR, 18% VGPR, 50% PR	11	Pönisch. BJH 2008[128]
+ Thal-Dex	23	5 (3–7)	26%	4% CR, 22% PR	3	Grey-Davies. BJH 2012[130]
+ Len-Dex	29	3 (1–6)	52%	24% VGPR, 28% PR	6.1	Lentzsch. Blood 2012[131]
+ Len-Pred	21	2 (1–2)	76%	5% sCR, 28% VGPR, 43% PR	48% @ 18m	Pönisch. BJH 2013[132]

^*All relapsing after ASCT